Cantor Fitzgerald Estimates XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the biopharmaceutical company will post earnings of ($3.58) per share for the year. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to analyst estimates of $1.64 million. During the same period in the prior year, the firm posted ($0.62) earnings per share.

Several other research firms also recently weighed in on XENE. HC Wainwright restated a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. The Goldman Sachs Group dropped their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Needham & Company LLC cut their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Royal Bank of Canada reduced their target price on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. One analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $54.82.

Xenon Pharmaceuticals Trading Down 0.1%

Shares of XENE stock traded down $0.04 during mid-day trading on Tuesday, reaching $32.76. The stock had a trading volume of 612,168 shares, compared to its average volume of 559,493. The company has a market cap of $2.51 billion, a P/E ratio of -11.62 and a beta of 1.09. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00. The business has a 50-day simple moving average of $32.85 and a 200 day simple moving average of $36.47.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D boosted its stake in Xenon Pharmaceuticals by 11.2% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 54,033 shares of the biopharmaceutical company's stock worth $2,118,000 after buying an additional 5,460 shares during the last quarter. HighMark Wealth Management LLC lifted its holdings in shares of Xenon Pharmaceuticals by 22.0% during the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after acquiring an additional 1,100 shares during the period. TimesSquare Capital Management LLC boosted its position in shares of Xenon Pharmaceuticals by 9.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 848,850 shares of the biopharmaceutical company's stock worth $33,275,000 after acquiring an additional 70,557 shares during the last quarter. Assetmark Inc. grew its holdings in Xenon Pharmaceuticals by 9.7% in the fourth quarter. Assetmark Inc. now owns 21,585 shares of the biopharmaceutical company's stock valued at $846,000 after purchasing an additional 1,915 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $797,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.